Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (48)

2024

  1. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

    Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 5, pp. 1304-1313

  2. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica

  3. How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 6

  4. Mechanism-Based Modeling of Perioperative Variations in Hemoglobin Concentration in Patients Undergoing Laparoscopic Surgery

    Anesthesia and Analgesia, Vol. 138, Núm. 1, pp. 141-151

  5. Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 49, Núm. 4, pp. 507-516

  6. Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 13, Núm. 4, pp. 638-648

2023

  1. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice

    Frontiers in Pharmacology, Vol. 14

  2. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

  3. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

  4. Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases

    Pharmaceutics, Vol. 15, Núm. 11

  5. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation

    European Journal of Pharmaceutical Sciences, Vol. 183

2022

  1. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3815-3830

  2. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy

    Clinical Microbiology and Infection, Vol. 28, Núm. 9, pp. 1287.e9-1287.e15

  3. Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 166-177

  4. Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 11, Núm. 5, pp. 581-593

2021

  1. A quantitative systems pharmacology model for acute viral hepatitis B

    Computational and Structural Biotechnology Journal, Vol. 19, pp. 4997-5007

  2. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  3. Enteric reabsorption processes and their impact on drug pharmacokinetics

    Scientific Reports, Vol. 11, Núm. 1

  4. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  5. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

    British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285